CA1027946A - Process for the preparation of 5-fluorouracil derivatives - Google Patents

Process for the preparation of 5-fluorouracil derivatives

Info

Publication number
CA1027946A
CA1027946A CA214,712A CA214712A CA1027946A CA 1027946 A CA1027946 A CA 1027946A CA 214712 A CA214712 A CA 214712A CA 1027946 A CA1027946 A CA 1027946A
Authority
CA
Canada
Prior art keywords
preparation
fluorouracil derivatives
fluorouracil
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA214,712A
Other languages
English (en)
French (fr)
Inventor
Haruki Mori
Masao Tada
Shoichiro Ozaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsui Pharmaceuticals Inc
Mitsui Toatsu Chemicals Inc
Original Assignee
Mitsui Pharmaceuticals Inc
Mitsui Toatsu Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Pharmaceuticals Inc, Mitsui Toatsu Chemicals Inc filed Critical Mitsui Pharmaceuticals Inc
Application granted granted Critical
Publication of CA1027946A publication Critical patent/CA1027946A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA214,712A 1973-11-28 1974-11-27 Process for the preparation of 5-fluorouracil derivatives Expired CA1027946A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP13279673A JPS5324952B2 (pt) 1973-11-28 1973-11-28
JP13279573A JPS5324951B2 (pt) 1973-11-28 1973-11-28
JP4661774A JPS5512015B2 (pt) 1973-11-28 1974-04-26

Publications (1)

Publication Number Publication Date
CA1027946A true CA1027946A (en) 1978-03-14

Family

ID=27292666

Family Applications (1)

Application Number Title Priority Date Filing Date
CA214,712A Expired CA1027946A (en) 1973-11-28 1974-11-27 Process for the preparation of 5-fluorouracil derivatives

Country Status (7)

Country Link
US (1) US3971784A (pt)
JP (3) JPS5324952B2 (pt)
CA (1) CA1027946A (pt)
CH (1) CH601258A5 (pt)
DE (1) DE2455423C3 (pt)
FR (1) FR2255910B1 (pt)
GB (1) GB1487335A (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2602175B2 (de) * 1975-01-22 1978-05-03 Asahi Kasei Kogyo K.K., Osaka (Japan) 1 -Alkanoyl-5-fluor-uracilderivate und ihre Verwendung
US4124765A (en) * 1975-05-13 1978-11-07 Ono Pharmaceutical Co., Ltd. 5-Fluorouracil derivatives
US4071519A (en) * 1975-11-05 1978-01-31 Mitsui Toatsu Chemicals, Incorporated 1-Carbamoyl-5-fluorouracil derivatives
JPS5331676A (en) * 1976-09-06 1978-03-25 Mitsui Toatsu Chem Inc Uracil derivatives and their preparation
JPS6052708B2 (ja) * 1976-12-24 1985-11-20 エーザイ株式会社 ５−フルオロウラシル系化合物およびそれを含有する抗腫瘍剤
US4349552A (en) 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
EP0010941B1 (en) * 1978-10-30 1982-05-12 Fujisawa Pharmaceutical Co., Ltd. 5-fluorouracil derivatives, preparation thereof and their pharmaceutical compositions
US4307098A (en) * 1978-12-14 1981-12-22 Imperial Chemical Industries Limited Pesticidal compositions and processes for treating plants
JPS5663966A (en) * 1979-10-29 1981-05-30 Tokyo Kinzoku Kogyo Kk Pyrimidine derivative and its preparation
JPS5767578A (en) * 1980-10-09 1982-04-24 Grelan Pharmaceut Co Ltd N-phthtalidy-5-fluorouracil derivative
JPS5785374A (en) * 1980-11-18 1982-05-28 Mitsui Toatsu Chem Inc 5-fluorouracil derivative and its preparation
FR2539412B1 (fr) * 1983-01-13 1986-02-21 Shoichiro Ozaki Derives du 5-fluoruracile et leurs utilisations therapeutiques en tant qu'agents carcinostatiques
DE3347795A1 (de) * 1983-01-14 1985-08-01 Ozaki, Shoichiro, Ehime Neue 1-(n-substituierte carbamoyl)-5-fluorouracil-derivate und krebshemmende mittel, in denen sie als aktive bestandteile enthalten sind
DE3301107A1 (de) 1983-01-14 1984-07-19 Ozaki, Shoichiro, Ehime Neue 1-(n-substituierte carbamoyl)-5-fluorouracil-derivate und krebshemmende mittel, in denen sie als aktive bestandteile enthalten sind
SU1235864A1 (ru) * 1983-03-11 1986-06-07 Отделение ордена Ленина института химической физики АН СССР Нитроксильные производные 5-фторурацила,обладающие противоопухолевой активностью
WO1989010361A1 (en) * 1988-04-27 1989-11-02 Kyowa Hakko Kogyo Co., Ltd. Novel compound and medicine containing same
HRP970239B1 (en) * 1997-05-09 2004-04-30 Inst Ru Er Bouekovic Process for the preparation of sulfonyl-pyrimidine derivatives with antitumor activity
ES2263238T3 (es) * 1998-03-30 2006-12-01 F. Hoffmann-La Roche Ag Procedimiento para la preparacion de antagonistas alfail-adrenoceptores.
US6235782B1 (en) 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
WO2000027403A1 (en) * 1998-11-12 2000-05-18 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a pyrimidine analog
US6235776B1 (en) 1998-11-12 2001-05-22 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3360520A (en) * 1964-05-01 1967-12-26 Du Pont 1, 3, 5, 6-tetrasurbstituted uracils

Also Published As

Publication number Publication date
GB1487335A (en) 1977-09-28
JPS50148365A (pt) 1975-11-27
DE2455423C3 (de) 1978-06-08
JPS5324952B2 (pt) 1978-07-24
JPS5088078A (pt) 1975-07-15
US3971784A (en) 1976-07-27
JPS5324951B2 (pt) 1978-07-24
DE2455423B2 (de) 1977-10-13
FR2255910B1 (pt) 1978-07-21
DE2455423A1 (de) 1975-06-05
JPS5512015B2 (pt) 1980-03-29
FR2255910A1 (pt) 1975-07-25
JPS5083379A (pt) 1975-07-05
CH601258A5 (pt) 1978-06-30

Similar Documents

Publication Publication Date Title
CA1027946A (en) Process for the preparation of 5-fluorouracil derivatives
CA989827A (en) Process for the preparation of 14-hydroxymorphinan derivatives
CA1027951A (en) Process for the preparation of 2,2,6,6-tetramethyl-4-oxopiperidine
CA1027950A (en) Process for the preparation of 2,2,6,6-tetramethyl-4-oxopiperidine
EG11318A (en) Process for the preparation of 7-amino-3-cephem derivatives
CA1032156A (en) Process for the preparation of 7-acylaminodesace-toxycephalosporanic acid derivatives
CA1027952A (en) Process for the preparation of 2,2,6,6-tetramethyl-4-oxopiperidine
CA1036169A (en) Process for the preparation of poly-n-alkyliminoalanes
CA1014974A (en) Process for the preparation of 5-chloro-2-toluidine
CA1033742A (en) Process for the preparation of quinoline derivatives
CA1029018A (en) Process for the preparation of benzothiadiazines
CA1022946A (en) Process for the preparation of new derivatives for thiazole 5-methanol
CA993871A (en) Process for the preparation of certain indolobenzazepine derivatives
CA1019726A (en) Process for the preparation of methylcobalamine from cyanocobalamine
CH609345A5 (en) Process for the preparation of pyrimidinoaminomethylergoline derivatives
ZA743764B (en) Process for the preparation of antibiotic derivatives
CA1021770A (en) Process for the preparation of desmosterol derivatives
CH610326A5 (en) Process for the preparation of novel 4-oxo-1-pyridinylpenicillin and -cephalosporin derivatives
CA1034497A (en) Process for the preparation of choleragen
CA1018165A (en) Process for the manufacture of pyrimidine derivatives
CA1022867A (en) Microbiological process for the preparation of oxoalkylxanthines
CA1035362A (en) Process for the preparation of 1,2,4-triazole derivatives
CH612956A5 (en) Process for the preparation of 1H-tetrazole-5-thiol derivatives
CA1026344A (en) Process for the preparation of oxadiazoline derivatives
AU487964B2 (en) Process for the preparation of 7-amino- 3 - cephem derivatives